Prot# GS-US-334-0154: A Phase 2b, Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) Tablet for 12 weeks in Genotype 1 or 4 HCV-Infected Subjects with Renal

  • Flamm, Steven L (PD/PI)

Project: Research project

Project Details

Effective start/end date6/8/166/8/19


  • Covance Inc. (Prot# GS-US-334-0154 // Prot# GS-US-334-0154)
  • Gilead Sciences, Inc (Prot# GS-US-334-0154 // Prot# GS-US-334-0154)